BioStrand (a subsidiary of IPA)’s Post

🚀 The landscape of #Biopharma R&D is undergoing a transformative shift! Historically plagued by low productivity, high failure rates, and lengthy development timelines, the industry now faces increasing pressure to innovate as patent cliffs loom and pipelines need replenishment. 🌟 Enter the era of #DigitalHealth tools in biopharma research or #TechBio. This movement is driving traditional biopharma companies to leverage the power of big data and advanced #AI, including #GenerativeAI. These technological advancements are / will significantly enhance the efficiency and effectiveness of R&D functions. 🇪🇺 #Europe is home to some of the most promising #TechBio innovators. Rising stars such as myNEO Therapeutics (Belgium), Concr (United Kingdom), Epigene Labs (France), kaiko.ai (Netherlands), and ADLIN Science (France) are leading the charge. 📅 Stay tuned over the next few days as Galen Growth | Insights You Can Trust profiles each #RisingStar company, highlighting their uniqueness. #Biopharma #TechBio #DigitalHealth #AI

Folks, If you are attending PepTalk this week, make sure you do not overlook the enlightening presentation by my glorious colleague Gilad Kaplan "Enhancement of Antibody Thermostability and Affinity by Computational Design in the Absence of Antigen" scheduled for this Friday at 9:35 am in the Antibody Design and Optimization workstream, which Gilad is also moderating. As Biologics drug developers we know first hand that engineering of the most potent, stable and successful biologic drug candidate requires significant time optimizing different properties of the molecule, like binding, stability and solubility. Machine Learning (ML) algorithms hold significant potential for faster optimization of Biologics and shortening the timelines to the clinic. Gilad's talk will present our approach to using ML to optimize antibodies for increased binding and thermostability without the need for any additional structural data. Tools such as these will allow high throughput optimization of antibodies early in the discovery phase, increasing the quality of drug candidates throughout selection. https://lnkd.in/eR6jygTe

A new paradigm for targeted quantitation. Move biomarker candidates from discovery to validation more efficiently, confidently, and at lower cost with breakthroughs in extended scale, massive throughput, higher sensitivity, greater specificity, and unrivaled productivity. #Biomarker Verification #Throughput

We are pleased to present the EY German Biotech Report 2024, which has been produced in close cooperation with BIO Deutschland e. V..   This year we are devoting special attention to the topic of AI in biotechnology. From simulating clinical trials to developing personalized medicines, AI holds the promise of ushering in the next wave of bioscientific innovation. For a deeper dive, download the full EY German Biotech Report 2024: https://lnkd.in/egnQsNa4   Let's discuss the future of biotech and AI – I welcome your thoughts and questions in the comments below.   #EYBiotech #BioDeutschland #Biotechnologie

The EY German Biotech Report is out, and guess what? This year it covers new opportunities brought about by the use of AI. Despite ariadne.ai ag being Swiss and the report focusing on the German market this is a strong affirmation for us that our strategy is on the right track. While our main focus at the moment is SPATIAL, our SaaS application for the analysis of spatial biology data, which is already being utilized by customers in the fields of neurodegenerative diseases and tumor-immunology, the rest of our AI-based product portfolio for high-content and high-throughput screens also plays a pivotal role in drug discovery. We are excited to continue pushing the boundaries of what's possible in biotech, leveraging AI to revolutionize research and development for our customers. The future looks promising, and we are eager to contribute to groundbreaking discoveries that can improve lives. I am looking forward to the presentation of the results at #cubexone in Mannheim. #EYBiotech #BioDeutschland #Biotechnologie #Biotechnology #Drugdiscovery #spatialbiology #spatialomics #AI #machinelearning #deeplearning

🔬 Exciting News in the World of Artificial Intelligence and Drug Development 🚀 AlphaFold, the groundbreaking software developed by GoogleAI, has been enhanced to propel the study of proteins 🧬 to new heights and accelerate drug development 💊. This upgrade marks a significant milestone in the intersection of technology and healthcare. 🌟 The upgraded AlphaFold software promises to revolutionize how we understand and manipulate proteins, unlocking vast potential in drug discovery and development. 👨🔬 Led by Demis Hassabis, Google’s AI chief, this advancement showcases the power of artificial intelligence in transforming complex scientific processes. 🧪 With enhanced capabilities, researchers and pharmaceutical companies can potentially expedite the discovery of novel drugs for various diseases, providing hope for improved treatments. 🔍 By offering a deeper understanding of protein structures, AlphaFold's upgrade opens doors to more precise drug targeting and design, potentially leading to more effective therapies. In conclusion, the evolution of AlphaFold stands as a testament to the incredible strides being made in AI-powered solutions for scientific innovation 🌐. This advancement not only holds promise for the future of drug development but also underscores the potential of AI to drive impactful change in various fields. Stay tuned for more groundbreaking developments! #ArtificialIntelligence #DrugDevelopment #AlphaFold #Innovation ⚛️🔝

AI and Radiomics in Drug Development: Challenges and Approaches, Upcoming Webinar Hosted by Xtalks — MediaContacts.co — #pin this #free #webinar #gain insights into the pivotal #role of radiomics and #AI in #drug #development as well as their #potential in streamlining processes and enabling #precision #medicine The #featured #speakers will #share real-world applications and their #impact on the drug development landscape. TORONTO, #Jan #4 #2024 #Discover an informative webinar delving into the #important and potential impacts of radiomics and #artificial #intelligence

Navigating the global markets in 2024 presents exciting opportunities, particularly in investments and pharmaceuticals. Here's a snapshot of the current landscape: The economic outlook remains cautiously optimistic, with sectors like tech and ESG investing leading the charge. 1. **Tech and AI**: Innovations in AI, driven by companies like NVIDIA, continue to attract significant investment. 2. **Sustainable Investments**: Green energy and sustainable infrastructure are seeing heightened interest. 1. **Biotech**: Breakthrough treatments in oncology and gene editing are poised for growth. 2. **Telehealth**: The expansion of telemedicine is making healthcare more accessible. Strategic investments in these areas can drive sustainable growth and innovation. #GlobalMarkets #Investment #Pharmaceuticals #TechInnovation #ESGInvesting

Kicking it off today! Breaking boundaries at hubXchange Europe, AI in drug discovery xchange Nov. 23, 2023. Team IPA is showcasing our cutting edge approach to optimizing antibody drug discovery as the HUB of Biotherapeutic Intelligence. Don't miss Arnout Van Hyfte, our Head of Products & Platforms at BioStrand (a subsidiary of IPA), presenting the poster "Leveraging the powerful, synergistic combination of in silico and wet lab technologies for accelerated lead selection" as well as the pivotal presentation "Knowledge extraction with smart data management". Don't miss the opportunity for 1:1 discussion with our technology leaders. Let's start the conversation on how it can seamlessly integrate into your workflows. https://lnkd.in/eTBRkN-m #AIinDrugDiscovery #Antibodies #DrugDiscovery #Biotechnology #TechBio #AI #ArtificialIntelligence

🚀 Harnessing AI for Pharma/Biotech Breakthroughs! 🌟 Dive into the future with us! Our latest white paper on AI is here to revolutionize your approach to drug discovery. 🧬💡 Why AI? Because it transforms raw data into lifesaving solutions. - 🎯 Identification: AI spots therapeutic targets hidden in complex biological data. - 💊 Drug Design: Generate molecules with the potential to heal. - 🔬 Discovery: Uncover biomarkers that steer towards precise treatments. - 🤖 Clinical Trial Optimization: AI designs better trials faster. - 🧪 Predictive Models: Anticipate drug effects and optimize therapy strategies. Unlock the potential of your data. Let AI take your research from the bench to the bedside swiftly and effectively! 🔗 Interested? Download the whitepaper below and dive into our detailed guide on leveraging AI in drug discovery! https://lnkd.in/gWKuAJZp #Pharma #Biotech #ArtificialIntelligence #DrugDiscovery #RevvitySignals